Gain-of-function mutations in <i>interleukin-7 receptor-α</i> ( <i>IL7R</i> ) in childhood acute lymphoblastic leukemias

Chen Shochat(Tel Aviv University), Noa Tal(Tel Aviv University), Obul Reddy Bandapalli(Heidelberg University), Chiara Palmi(University of Milano-Bicocca), Ithamar Ganmore(Tel Aviv University), Geertruy te Kronnie(University of Padua), Gunnar Cario(University Hospital Schleswig-Holstein), Giovanni Cazzaniga(University of Milano-Bicocca), Andreas E. Kulozik(Heidelberg University), Martin Stanulla(University Hospital Schleswig-Holstein), Martin Schrappe(University Hospital Schleswig-Holstein), Andrea Biondi(University of Milano-Bicocca), Giuseppe Basso(University of Padua), Dani Bercovich(Migal - Galilee Technology Center), Martina U. Muckenthaler(Heidelberg University), Shai Izraeli(Tel Aviv University)
The Journal of Experimental Medicine
May 2, 2011
Cited by 347Open Access
Full Text

Abstract

Interleukin-7 receptor α (IL7R) is required for normal lymphoid development. Loss-of-function mutations in this gene cause autosomal recessive severe combined immune deficiency. Here, we describe somatic gain-of-function mutations in IL7R in pediatric B and T acute lymphoblastic leukemias. The mutations cause either a serine-to-cysteine substitution at amino acid 185 in the extracellular domain (4 patients) or in-frame insertions and deletions in the transmembrane domain (35 patients). In B cell precursor leukemias, the mutations were associated with the aberrant expression of cytokine receptor-like factor 2 (CRLF2), and the mutant IL-7R proteins formed a functional receptor with CRLF2 for thymic stromal lymphopoietin (TSLP). Biochemical and functional assays reveal that these IL7R mutations are activating mutations conferring cytokine-independent growth of progenitor lymphoid cells. A cysteine, included in all but three of the mutated IL-7R alleles, is essential for the constitutive activation of the receptor. This is the first demonstration of gain-of-function mutations of IL7R. Our current and recent observations of mutations in IL7R and CRLF2, respectively suggest that the addition of cysteine to the juxtamembranous domains is a general mechanism for mutational activation of type I cytokine receptors in leukemia.


Related Papers

No related papers found

Powered by citation graph analysis